about
Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients.Clinical and Molecular Heterogeneity of RTEL1 DeficiencyValidation and application of a high-performance liquid chromatographic-based assay for determination of the inosine 5'-monophosphate dehydrogenase activity in erythrocytes.Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005.PGK1 as predictor of CXCR4 expression, bone marrow metastases and survival in neuroblastoma.Methotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia.Outcomes after induction failure in childhood acute lymphoblastic leukemia.Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup studyDenosumab: a potential new and innovative treatment option for aneurysmal bone cysts.Influence of Cranial Radiotherapy on Outcome in Children With Acute Lymphoblastic Leukemia Treated With Contemporary TherapyIndependent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL.Second malignant neoplasms after treatment of childhood acute lymphoblastic leukemia.Pediatric Acute Lymphoblastic Leukemia: Efficacy and safety of recombinant E. coli-asparaginase in infants (less than one year of age) with acute lymphoblastic leukemia.Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group.Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: an observational Ponte di Legno Toxicity Working Group study.Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation.Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus.The long-term impact of in vitro drug sensitivity on risk stratification and treatment outcome in acute lymphoblastic leukemia of childhood (CoALL 06-97).Outcome of children and adolescents with relapsed acute lymphoblastic leukaemia and non-response to salvage protocol therapy: a retrospective analysis of the ALL-REZ BFM Study Group.Survivin and its prognostic significance in pediatric acute B-cell precursor lymphoblastic leukemia.Impact of reduction of therapy on infectious complications in childhood acute lymphoblastic leukemia.Refinement of IKZF1 recombination hotspots in pediatric BCP-ALL patientsRapid Capture Next-Generation Sequencing in Clinical Diagnostics of Kinase Pathway Aberrations in B-Cell Precursor ALL.Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia.Corrigendum: Clinical and Molecular Heterogeneity of RTEL1 Deficiency.The association of aberrant folylpolyglutamate synthetase splicing with ex vivo methotrexate resistance and clinical outcome in childhood acute lymphoblastic leukemiaSecondary malignant neoplasms after intensive treatment of relapsed acute lymphoblastic leukaemia in childhood.BCR-ABL1-like cases in pediatric acute lymphoblastic leukemia: a comparison between DCOG/Erasmus MC and COG/St. Jude signatures.Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90.Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group.Fatal neurological side-effects with necrosis of spinal cord following nelarabine treatment in a child with relapsed T-cell acute lymphoblastic leukemia.Outcomes of treatment for relapsed acute lymphoblastic leukaemia in children with Down syndrome.HG-34HIGH-GRADE GLIOMA ARISING IN SURVIVORS OF PEDIATRIC ACUTE LYMPHOBLASTIC MALIGNANCIES: A COOPERATIVE ANALYSIS OF THE GERMAN HIT-HGG/-GBM AND ALL-BFM/COALL STUDIES.Interference free and simplyfied liquid chromatography-based determination of thiopurine S-methyltransferase activity in erythrocytes.Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95/96.Clofarabine in combination with pegylated asparaginase in the frontline treatment of childhood acute lymphoblastic leukaemia: a feasibility report from the CoALL 08-09 trial.Results and conclusions of the European Intergroup EURO-LB02 trial in children and adolescents with lymphoblastic lymphoma.Lineage switch under blinatumomab treatment of relapsed common acute lymphoblastic leukemia without MLL rearrangement.Comment on: "Successful use of nitrous oxide during lumbar punctures: A call for nitrous oxide in pediatric oncology clinics".Osteonecrosis develops independently from radiological leukemic infiltration of bone in adolescents with acute lymphoblastic leukemia - first findings of the OPAL trial.
P50
Q33573735-97D8B551-0B46-4782-9677-88B123FE74EEQ33619571-59A89E00-C542-4AA9-8F18-30D5211B8F32Q33996154-4ADA9307-F3AD-47CB-835B-876104427C4EQ34488796-457C9471-9E84-4AA2-8DA9-77B0A39F4DA8Q35078162-E89C11C7-AC0C-45E3-9CE4-970CEF3549A2Q35684384-80AF577D-AAAE-47F9-9BEF-58CD6A30903BQ36029619-A0E5AC84-BF1C-4883-BF0C-F9F6BAC15D9DQ36201257-6C605A99-3655-4020-80A3-354BBC55A5E0Q36912837-206B129B-6C03-4A67-8122-675FA800FA1AQ36914357-D2133DC4-4AFD-42BC-8E51-7FAC15C78A68Q37226741-F7A78ACD-B158-48FC-8F20-D7CB64763A4AQ37252283-55A35717-D71F-478A-8201-C1C4CEF2EAFDQ37273166-D0DD80D0-F24A-4F12-AAF7-EC0D6D3ABB34Q37429718-1730239F-0950-4205-A68B-B728BCA6E903Q38665804-3B24D2DC-8464-4B5D-BAA6-F9B6ADBED526Q38755617-ABE28C07-9D50-4FA0-898A-752D675258D1Q38864711-D8472F56-5FBC-4988-BC1A-5E25567A8851Q39205653-D7578B99-0798-40DA-A901-901526B239F3Q39824851-8AB10618-3F66-4900-A48B-80E022B5B886Q40191535-477929CD-C9A9-45F1-92A6-2C293DC9A434Q40444406-1CAFA141-D540-4C83-B77C-49CC7C094948Q40582741-54A9DF3B-CF52-4D04-B9C1-4E4D1AD9AE61Q40836915-ED3BD214-152F-4662-AE0F-256CE8A75962Q42315787-67683497-FD49-4374-856E-313F25EE3D2EQ42371901-9C9EB69C-E22D-49AA-869C-586F3BEAF7E5Q42399827-C153D771-295B-496F-8F8D-CA5F5FC78066Q42521150-4EB3DB51-0274-4C26-9FD7-BB2DA1EE88F7Q42943355-4FA05578-ACFD-45D5-B2F9-24160595FF6AQ43102321-9E3F29A1-8A7C-4173-84F5-4E8903D1CAECQ44706813-A50DC13B-5D9A-475C-B027-56F97136448DQ45130144-BE88F713-4B39-4CF0-B7FC-94F832310FD3Q45723589-BC90FA5B-3540-4593-8421-9F2FC4693FE2Q46351476-CD8FBD49-D968-4067-99F2-6A6F7EEDCBE6Q46493262-0B37EBAD-C68A-44C9-A530-119D27582230Q46676913-B1036253-E6F2-4106-B48A-3ED9A6016643Q46971601-7FD50FBD-1540-492E-91F1-B008F6032329Q47103786-6769C4F0-AD06-40E9-A7E9-BEBBE74FF652Q47779196-F6C42456-C7CF-4A9D-BAD8-CD8D31C04758Q47891019-15F90127-32DB-43B5-B710-159D77475E44Q48293406-4CA71809-A67C-426B-8E38-86E6FBC4A25C
P50
name
Gabriele Escherich
@en
Gabriele Escherich
@nl
type
label
Gabriele Escherich
@en
Gabriele Escherich
@nl
prefLabel
Gabriele Escherich
@en
Gabriele Escherich
@nl